This clinical reference guide provides practical prescribing guidance and monitoring considerations for transdermal estradiol as an androgen deprivation therapy (ADT) option for prostate cancer.
The guide also includes a summary of the PATCH/STAMPEDE Phase III clinical results, relevant NCCN guideline updates, and supporting scientific references.
View or download the complete physician prescription guide below.
ESTRADIOL PATCH
PHYSICIAN PRESCRIPTION GUIDE & CLINICAL REFERENCE
by Paul Schellhammer, MD | November 15, 2026
Official PATCH protocol:
- Apply four, 0.1 mg/24 hr estradiol patches (generic permitted) simultaneously to upper buttocks or hips, changed twice weekly. Reduce number of patches to three when T < 50 ng/dl.
Monitoring and Practical Considerations:
– Measure T and PSA monthly for 3 months, then increase to quarterly measurements.
– Optionally adjust the number of patches to reach a desirable T < 20 ng/dl.
– Clean application site with rubbing alcohol to remove skin oils before applying patches.
– Optionally pre-treat application site with a steroid nasal spray (e.g., Nasalcort™ or Flonase™) to reduce any skin irritation.
– Optionally rotate patch site location to reduce any skin irritation.
– Optionally use electron beam breast irradiation prior to applying patches. [refs]
– Optionally apply 1% diclofenac gel, and/or hot packs, to breasts and nipples. [ref]
– Experiencing mastalgia symptoms indicates that a significant serum level of estradiol has been reached.
– Do not use tamoxifen, as it will block estradiol’s ability to suppress testosterone.
– Strongly suggest getting a baseline DEXA scan.
– Advise that using bone protective drugs may not be needed with estradiol patch ADT.
– Offer to write a letter to the patient’s insurance company, referencing the 2026 NEJM paper, to obtain insurance coverage.
NCCN GUIDELINE UPDATE:
– The NCCN Prostate Cancer Guidelines were recently updated to Version 1.2027. Transdermal estradiol is now recommended as an option for ADT when combined with radiation therapy.
PATCH / STAMPEDE Phase-III RCT
SUMMARY OF PHASE-III CLINICAL RESULTS
Results of the combined PATCH/STAMPEDE Phase-III trial were published by Langley et al. in the New England Journal of Medicine (2026) and are summarized below:
https://pubmed.ncbi.nlm.nih.gov/41880608/
| OUTCOME | RESULTS |
| TESTOSTERONE SUPPRESSION | Transdermal estradiol (tE2) ADT suppressed testosterone below traditional castrate threshold level (T < 50 ng/dl) in 94% of men after one year. Same results for LHRHa ADT. |
| PSA REDUCTION | tE2 ADT reduced PSA by 50% in 99% of men, and it reduced PSA by 90% in 85% of men. Same results for LHRHa ADT. |
| SURVIVAL RATES | tE2 ADT was non-inferior compared to LHRHa ADT in terms of 3-year Metastasis-Free Survival and 5-year Overall Survival rates (81.1% with tE2 ADT versus 79.2% with LHRHa ADT). |
| SAFETY | tE2 ADT was equally as safe as LHRHa ADT, in terms of thromboembolic and cardiovascular events. |
| BONE DENSITY | tE2 ADT increased bone mineral density by 6%, versus a loss of -1.5% with LHRHa ADT, after one year. |
| FRACTURE RATES | tE2 ADT reduced fracture rates by 50% when compared to LHRHa ADT, at both 5 and 10 years. |
| HOT FLASHES | The fraction of men experiencing moderate to severe hot flashes was 7% for tE2 ADT versus 37% for LHRHa ADT. |
| METABOLIC SYNDROME | Lipid profiles, blood glucose, and blood pressure are better with tE2 ADT compared to LHRHa ADT. |
| FATIGUE | The fraction of men experiencing significant fatigue was 16% for tE2 ADT versus 25% for LHRHa ADT. |
| GYNECOMASTIA | The fraction of men experiencing symptomatic gynecomastia was 38% for tE2 ADT versus 9% for LHRHa ADT. |
REFERENCES
Colak T, Ipek T, Kanik A, Ogetman Z, Aydin S. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196(4):525-530. doi:10.1016/S1072-7515(02)01893-8. https://pubmed.ncbi.nlm.nih.gov/12691925/
Ghadjar P, Aebersold DM, Albrecht C, et al. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO working group prostate cancer. Strahlenther Onkol. 2020;196:589-597. doi:10.1007/s00066-020-01598-9. https://pubmed.ncbi.nlm.nih.gov/32166452/
Gilbert DC, Duong T, Kynaston HG, et al. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU Int. 2017;119(5):667-675. doi:10.1111/bju.13687. https://pubmed.ncbi.nlm.nih.gov/27753182/
Langley RE, Kynaston HG, Alhasso AA et al. A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: Luteinising hormone-releasing hormone agonists versus transdermal Oestradiol. Eur Urol 2016;69:1016–1025. doi: 10.1016/j.eururo.2015.11.030. https://pubmed.ncbi.nlm.nih.gov/26707868/
Langley RE, Cafferty FH, Alhasso AA, et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol. 2013;14(4):306-316. doi:10.1016/S1470-2045(13)70025-1. https://pubmed.ncbi.nlm.nih.gov/23465742/
Langley RE, Gilbert DC, Mangar S et al. Transdermal estradiol patches in locally advanced prostate cancer. New Engl J Med 2026;394:1595–1607. doi: 10.1056/NEJMoa2511781. https://pubmed.ncbi.nlm.nih.gov/41880608/
Langley RE, Gilbert DC, Duong T, et al. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised PATCH trial programme. Lancet. 2021;397:581-591. doi:10.1016/S0140-6736(21)00100-8. https://pubmed.ncbi.nlm.nih.gov/33581820/
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2027
Sears C, Watson R, Brown E, Abbas B, Schellhammer P, Wassersug R. Gynaecomastia secondary to transdermal oestradiol used for androgen deprivation therapy: informed reality vs subjective fear. BJU Int. 2026;138(5):815-821. doi:10.1111/bju.70374. https://pubmed.ncbi.nlm.nih.gov/42446241/
Tsuboi I, Schulz RJ, Laukhtina E, et al. Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: a systematic review and meta-analysis of randomized controlled trials. Eur Urol Open Sci. 2025;73:31-42. doi: 10.1016/j.euros.2025.01.001. https://pubmed.ncbi.nlm.nih.gov/39935942/
Widmark A, Fossa SD, Lundmo P, et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology. 2003;61:145-151. doi: 10.1016/s0090-4295(02)02107-6. https://pubmed.ncbi.nlm.nih.gov/12559286/
Wilson ME, Mook D, Graves F, et al. Tamoxifen is an estrogen antagonist on gonadotropin secretion and responsiveness of the hypothalamic-pituitary- adrenal Axis in female monkeys. Endocrine 2003;22:305–316. doi: 10.1385/ENDO:22:3:305. https://pubmed.ncbi.nlm.nih.gov/14709804/
